期刊文献+

游离前列腺特异性抗原性能指标的建立 被引量:4

Establishment of performance indicators for f-PSA
在线阅读 下载PDF
导出
摘要 目的建立Axceed 260磁微粒全自动化学发光免疫分析仪检测游离前列腺特异性抗原(f-PSA)的空白限(LoB)、最低检出限(LoD)及定量检出限(LoQ)。方法参照美国临床实验室标准化协会2012年颁发的EP17-A2《临床实验室评价检测能力(第2版)》,将f-PSA的空白样品及系列低浓度样品在Axceed 260磁微粒全自动化学发光免疫分析系统进行检测,根据数据的分布规律,采用相应的统计学方法,确定该方法检测f-PSA的LoB、LoD及LoQ。结果 f-PSA的LoB为0.05ng/mL,LoD为0.16ng/mL,LoQ为0.35ng/mL。结论建立的Axceed 260磁微粒全自动化学发光免疫分析系统f-PSA的LoB、LoD、LoQ,其检测能力符合临床检验要求。 Objective To establish the limit of blank (LoB),the limit of detection (LoD) and the limit of quantitation (LoQ) for the detection of f-PSA by the Axceed 260 automatic magnetic particles chemiluminescence immunoassay (MCLIA) analyzer system.Methods According to CLSI EP17-A2 protocol,f-PSA blank sample and a series of low concerntration samples were performed by the Axceed 260 MCLIA detection.According to the data distribution,the corresponding statistical method was adopted to establish the MCLIA detection of LoB,LoD and LoQ of f-PSA by the manual operation.Results LoB of f-PSA measured by the manual operation was 0.05 ng/mL,LoD was 0.16 ng/mL and LoQ was 0.35 ng/mL.Conclusion The established LoB,LoQ and LoQ of f-PSA in the clinical laboratory,its detection capability meets the clinical requirements.
出处 《检验医学与临床》 CAS 2017年第14期2097-2099,2102,共4页 Laboratory Medicine and Clinic
关键词 游离前列腺特异性抗原 磁微粒化学发光 空白限 检出限 定量检出限 f-PSA magnetic particles chemiluminescence immunoassay limit of blank limit of detection limit of quantitation
  • 相关文献

参考文献8

二级参考文献690

  • 1田兴珍,陆建刚,曹东,吴桂莲,周婷,孙文龙.ADVIA centaur XP化学发光免疫分析系统性能验证方法[J].宁夏医科大学学报,2013,35(8):947-949. 被引量:2
  • 2Roberto Catanzaro,Michele Milazzo,Silvia Arona,Chiara Sapienza,Dario Vasta,Domenico Arcoria,Francesco Marotta.Diagnostic accuracy of enhanced liver fibrosis test to assess liver fibrosis in patients with chronic hepatitis C[J].Hepatobiliary & Pancreatic Diseases International,2013,12(5):500-507. 被引量:3
  • 3杨晓达,常文保,慈云祥.免疫分析法进展[J].化学进展,1995,7(2):83-97. 被引量:12
  • 4张祥瑞,朱岚,黄飚,李跃松,刘海燕.游离型PSA时间分辨荧光免疫分析法的建立[J].中华肿瘤防治杂志,2007,14(4):277-279. 被引量:3
  • 5WANG M C, PAPSIDERO L D, KURIYAMA M, et al. Prostate antigen: A new potential marker for prostatic cancer[J]. Prostate, 1981, 2 : 89-96.
  • 6CHRISTENSSON A, LAURELL C B, LILJA H. Enzymatic activity of the prostate-specific antigen and its reactions with extracellular serine protease inhibitors [J]. Eur J Biochem, 1990, 194: 755-763.
  • 7LEINONEN J, ZHANG W M, STENMAN U H. Complex formation between PSA isoenzymes and protease inhibitors[J]. J Urol, 1996, 155: 1 099-1 103.
  • 8LILJA H, CHRISTENSSON A, DAHLEN U, et al. Prostate-specific antigen in serum occurs predominantly in complex with alpha-1-antichymotrypsin[J]. Clin Chem, 1991, 37: 1 618-1 625.
  • 9BABAIAN R J, FRITSCHE H A, EVANS R B.Prostate-specific antigen and prostate gland volume: Correlation and clinical application[J]. J Clin Lab Anal, 1990, 4: 135-137.
  • 10ARMBUSTER D A. Prostate-specific antigen: Biochemistry, analytical methods,and clinical applieation[J]. Clin Chem, 1993, 39: 181-195.

共引文献120

同被引文献39

引证文献4

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部